Prevalence of Long COVID After SARS-CoV-2 in Pregnancy Is 9.3 Percent

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 30, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, July 30, 2024 -- The prevalence of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) after SARS-CoV-2 infection during pregnancy is 9.3 percent during the 10.3 months after first infection, according to a study published online July 11 in Obstetrics & Gynecology.

Torri D. Metz, M.D., from the University of Utah Health in Salt Lake City, and colleagues conducted a multicenter cohort study involving individuals who were pregnant during their first SARS-CoV-2 infection to estimate the prevalence of PASC and characterize associated risk factors.

Of the 1,502 participants, 61.1 percent had their first COVID-19 infection during omicron variant dominance; 51.4 percent were fully vaccinated before infection; and 12.1 percent were enrolled within 30 days of acute infection. At a median of 10.3 months after first infection, the researchers found that the prevalence of PASC was 9.3 percent. Among individuals with PASC, the most common symptoms were postexertional malaise, fatigue, and gastrointestinal symptoms (77.7, 76.3, and 61.2 percent, respectively). An increased prevalence of PASC was seen in association with a history of obesity and depression or anxiety disorder before first infection (adjusted odds ratios, 1.65 and 2.64, respectively), economic hardship (self-reported difficulty covering expenses; adjusted odds ratio, 1.57), and treatment with oxygen during acute SARS-CoV-2 infection (adjusted odds ratio, 1.86).

"We need to have this on our radar as we're seeing patients. It's something we really don't want to miss," Metz said in a statement. "And we want to get people referred to appropriate specialists who treat long COVID."

Several authors disclosed ties to the pharmaceutical and medical technology industries.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-31 03:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords